Citations

Clear

3042 citation(s) found for "Kumar, S".

HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products
Kumar, Swati, Morrison, James H. , Dingli, David , Poeschla, Eric M. , Dingli, David

Mayo Clinic

Journal of Virology | May 17, 2018 | Volume: 92 | Issue: 16 | Pages: No page available

10.1128/jvi.00001-18 | PMID 29769349 Get It

Much remains unknown about how TREX1 influences HIV-1 replication: whether it targets full-length viral DNA versus partial intermediates, how intracellular TREX1 protein levels correlate with ISG induction, and whether TREX1 digestion of cytoplasmic DNA and subsequent cGAS pathway activation affects both initial and subsequent cycles of infection. To answer these questions, we experimentally varied the intracellular level of TREX1 and showed that this strongly determines the innate immunogenicity of HIV-1. In addition, several lines of evidence, including time-of-addition experiments with drugs that impair reverse transcription or capsid integrity, showed that the pathogen-associated molecular patterns sensed after viral entry contain DNA, are TREX1 and cGAS substrates, and are derived from incomplete reverse transcriptase (RT) products. In contrast, the experiments demonstrate that full-length integration-competent viral DNA is immune to TREX1. Treatment approaches that reduce TREX1 levels or facilitate release of DNA intermediates may advantageously combine enhanced innate immunity with antiviral effects.
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Milani, Paolo , Perlini, Stefano , Mussinelli, Roberta , Lacy, Martha Q. , Kumar, Shaji , Merlini, Giampaolo , Hayman, Suzanne R. , Dingli, David , Klarich, Kyle W. , Lust, John A., Lin, Yi , Kapoor, Prashant , Pellikka, Patricia A. , Hwa, Yi L. , Zeldenrust, Stephen R., Kyle, Robert A. , Grogan, Martha , Merlini, Giampaolo , Milani, Paolo , Pellikka, Patricia A , Dingli, David , Lin, Yi , Dispenzieri, Angela , Scott, Christopher G. , Gertz, Morie A. , Buadi, Francis K. , Maurer, Matthew J. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent , Mussinelli, Roberta , Perlini, Stefano

Mayo Clinic

Circulation: Cardiovascular Imaging | May 11, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circimaging.117.006588 | PMID 29752392 Get It

Background: Heart involvement is the most important prognostic determinant in AL amyloidosis patients. Echocardiography is a cornerstone for the diagnosis and provides important prognostic information. Methods and Results: We studied 754 patients with AL amyloidosis who underwent echocardiographic assessment at the Mayo Clinic, including a Doppler-derived measurement of stroke volume (SV) within 30 days of their diagnosis to explore the prognostic role of echocardiographic variables in the context of a well-established soluble cardiac biomarker staging system. Reproducibility of SV, myocardial contraction fraction, and left ventricular strain was assessed in a separate, yet comparable, study cohort of 150 patients from the Pavia Amyloidosis Center. The echocardiographic measures most predictive for overall survival were SV index <33 mL/min, myocardial contraction fraction <34%, and cardiac index <2.4 L/min/m 2 with respective hazard ratios (95% confidence intervals) of 2.95 (2.37–3.66), 2.36 (1.96–2.85), and 2.32 (1.91–2.80). For the subset that had left ventricular strain performed, the prognostic cut point was −14% (hazard ratios, 2.70; 95% confidence intervals, 1.84–3.96). Each parameter was independent of systolic blood pressure, Mayo staging system (NT-proBNP [N-terminal pro-B-type natriuretic peptide] and troponin), and ejection fraction on multivariable analysis. Simple predictive models for survival, including biomarker staging along with SV index or left ventricular strain, were generated. Conclusions: SV index prognostic performance was similar to left ventricular strain in predicting survival in AL amyloidosis, independently of biomarker staging. Because SV index is routinely calculated and widely available, it could serve as the preferred echocardiographic measure to predict outcomes in AL amyloidosis patients.
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Kumar, Shaji , Durie, Brian G.M. , Nahi, Hareth , Vij, Ravi , Kastritis, Efstathios , Terpos, Evangelos , Leleu, Xavier , Beksaç, Meral , Goldschmidt, Hartmut , Hillengaß, Jens , Khan, Imran , Lam, Annette , Beksaç, Meral , Terpos, Evangelos , Kastritis, Efstathios , Beksac, Meral , Dimopoulos, Meletios Α. , Su, Zhuo T. , Hutton, Brian F. , Cameron, Chris G , Nahi, Hareth

Mayo Clinic

Leukemia & Lymphoma | May 9, 2018 | Volume: 60 | Issue: 1 | Pages: 163-171

10.1080/10428194.2018.1459609 | PMID 29741423 Get It

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar, Anita J. , Hemmer, Michael, Arora, Mukta , Pidala, Joseph A. , Couriel, Daniel R. , Aljurf, Mahmoud , Cahn, Jean‐Yves, Cairo, Mitchell S. , Farhan, Shatha , Hale, Gregory A., Hashmi, Shahrukh K. , Inamoto, Yoshihiro , Kamble, Rammurti T., Kharfan‐Dabaja, Mohamed A. , MacMillan, Margaret L. , Marks, David I. , Norkin, Maxim , Ringdén, Olle , Schouten, Harry C. , Solh, Melhem , Urbano-Ispizúa, Álvaro , Verdonck, Leo F. , Hamilton, Betty K. , Majhail, Navneet S. , Loren, Alison W. , Ringden, Olov , Majhail, Navneet S , Kim, Soyoung , Spellman, Stephen R. , Alousi, Amin Majid , Cahn, Jean‐Yves , Cutler, Corey S. , Gergis, Usama , Nakasone, Hideki , Qayed, Muna , Schultz, Kirk R. , Teshima, Takanori , Gale, Robert Peter

Mayo Clinic

Blood Advances | May 8, 2018 | Volume: 2 | Issue: 9 | Pages: 1022-1031

10.1182/bloodadvances.2017013052 | PMID 29739773 Get It

Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
Early Intervention in Multiple Myeloma—Exploring New Frontiers
Kumar, Shaji

Mayo Clinic

Oncology & Hematology Review (US) | May 4, 2018 | Volume: 14 | Issue: 1 | Pages: 12

10.17925/ohr.2018.14.1.12 Get It

The progress that has been made in myeloma during the past decade has been remarkable, and paralleled by few other cancers, if any. This has come through a combination of better understanding of the disease biology, introduction of new drug classes, development of rational and highly effective combinations, extended duration of therapy, and better supportive care. However, we are still far from being able to label myeloma as a curable disease given the inability to predict who, if any, will be able to have a normal life expectancy after a diagnosis of myeloma. We clearly need a different approach to achieve this elusive goal. What might that be?
Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation
Chakraborty, Rajshekhar , Muchtar, Eli , Kumar, Shaji , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Lacy, Martha Q. , Warsame, Rahma , Kourelis, Taxiarchis , Kumar, Shaji K , Buadi, Francis K. , Gonsalves, Wilson , Muchtar, E , Chakraborty, Rajshekhar , Dingli, David , Dispenzieri, Angela , Hogan, William J. , Leung, Nelson , Gonsalves, Wilson I. , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | April 30, 2018 | Volume: 182 | Issue: 1 | Pages: 71-77

10.1111/bjh.15244 | PMID 29707759 Get It

SummaryThe optimal duration of induction therapy (IT) in transplant‐eligible multiple myeloma (MM) patients in not well defined, resulting in a wide variation in clinical practice. The objective of our study was to determine whether the duration of IT in patients undergoing upfront autologous stem cell transplantation (ASCT) has an impact on progression‐free survival (PFS) in the era of proteasome inhibitors and immunomodulatory drugs. A total of 596 patients who underwent ASCT at Mayo Clinic between 2007 and 2014 were included. The patients were divided into two cohorts based on the duration of IT: IT ≤ 4 and IT > 4 months. At a median follow‐up of 54·5 months from ASCT, the median PFS in the IT ≤ 4 group was 28 months [95% confidence interval (CI), 25–33], compared to 26 months in the IT > 4 group (95% CI, 24–31) [P = 0·605]. There was no significant difference in overall survival (OS) in the two groups (P = 0·904). The lack of impact of IT duration on PFS and OS was consistent in subgroups with high‐risk features at diagnosis (International Staging System III or high‐risk cytogenetics) and different depths of pre‐transplant response [≥very good partial response (VGPR) and <VGPR]. In conclusion, prolonging the duration of IT beyond 4 months does not impact survival in patients with newly diagnosed MM who complete a single line of IT followed by consolidation with ASCT.
Using mean frequency estimation algorithms for unambiguous identification and visualization of an acoustically active catheter
Kim, Bae Hyeong, Bëlohlávek, Marek , Kumar, Viksit , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | April 17, 2018 | Volume: 143 | Issue: 3_Supplement | Pages: 1930-1930

10.1121/1.5036307 Get It

Minimally invasive procedures using ultrasound are becoming prominent, especially in applications like biopsy, catheter guidance, and surgeries. In our previous work a catheter tip is fitted with a miniature omnidirectional piezoelectric crystal; the ultrasonic field from the imaging array and the piezoelectric crystal interact resulting in a symmetric Doppler shift. Previously, a frequency domain algorithm was used to identify pixels having the symmetric Doppler shift. The identified pixels can then be visualized on B-mode and color map with a unique color thus representing the location of the catheter tip. However, frequency domain algorithms are computationally expensive and require changes to data workflow. Using mean frequency estimators with symmetric Doppler shift results in the catheter tip being displayed as zero mean noise making it hard to distinguish from color Doppler noise. To overcome this limitation, complex demodulation can be used. Modulating the time domain signal with sine and cosine by the piezoelectric excitation frequency and summing them up results in cancellation of one of the symmetric Doppler components. With only one frequency component remaining mean frequency estimators can be used to identify the location of the catheter. The presented algorithm has lower computational complexity and requires minimal change in software design.
Quantitative morphological analysis of microvasculature in thyroid nodules using non-contrast high-resolution Doppler imaging
Ghavami, Siavash , Gregory, Adriana , Kim, Bae Hyeong, Viksit, Kumar, Webb, Jeremy, Bayat, Mahdi , Fatemi, Mostafa , Alizad, Azra

Mayo Clinic

The Journal of the Acoustical Society of America | April 17, 2018 | Volume: 143 | Issue: 3_Supplement | Pages: 1901-1902

10.1121/1.5036190 Get It

We hypothesize that pattern of microvasculature in the thyroid nodules can be a biomarker of thyroid cancer. In this study, morphological features of microvasculature networks are assessed as potential biomarkers for differentiation of benign, suspicious and malignant thyroid nodules. This prospective study included n = 81 patients, with a total of 61 benign, 12 suspicious and 8 malignant nodules verfied by pathology and cytology findings. Thyroid nodules were first identified using conventional B-mode ultrasound. A sequence of raw ultrasound data were acquired from each nodule site in two perpendicular planes at ~600 frames/sec. Power Doppler image of the microvasculature was formed using singular value decomposition clutter removal filtering. Gross images were further processed using a combination of morphology and Hessian-based vessel enhancement filtering. Background-free images of the microvasculature networks were segmented (vessels segment length &gt;385μm and diameter &gt;90μm) for morphological analysis. Using a Bayesian framework, measures of vessels density, diameter and tortuosity were tested for significant differences in the three groups. Among all measures, the probability of vessel diameter &gt;600μm in benign cases was significantly higher than that in malignant cases with the p-value &lt;0.01 using Wilcoxon-Rank-Sum test, suggesting reliable cancer detection performance of the proposed method. [Acknowledgment: NIH Grant EB17213.]
Quantifying nonlinear elasticity modulus of tissue-like solids using acoustic radiation force
Panahandeh-Shahraki, Danial, Kinnick, Randall R., Ghavami, Siavash , Guzina, Bojan B. , Kumar, Viksit , Urban, Matthew W. , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | April 17, 2018 | Volume: 143 | Issue: 3_Supplement | Pages: 1802-1802

10.1121/1.5035900 Get It

As shown in a recent study, estimation of the magnitude of the acoustic radiation force (ARF) in isotropic tissue-like solids is the key to measuring a third-order nonlinear modulus of elasticity (C)—responsible for coupling the shear and volumetric constitutive responses of a material. Due to experimental limitations, a direct measurement of the ARF in tissue is however difficult. To overcome this problem, we deploy 3D elastodynamic finite element (EFE) simulations of the ARF experiment in tissue-mimicking phantoms to estimate (i) the “background” shear modulus from the phase of the induced shear waves; (ii) the ARF magnitude from the shear wave amplitude, and (iii) the modulus C from the knowledge of the ARF. In this way, by interpreting the ARF-generated shear waves through the prism of 3D-EFE simulations, we facilitate local estimation of the nonlinear C modulus with spatial resolution equaling the size of the focal region. We call this method the C-Elastography (CE). In this study, the CE technique is applied to gelatin phantoms containing an agar-based inclusion. The profiles of the C-modulus in phantoms tested demonstrate good correlation with the phantom geometry, showing marked (and sharp) C-contrast at push points acting on the inclusion. [Acknowledgment: NIH-Grant EB23113.]
Time to plateau as a predictor of survival in newly diagnosed multiple myeloma
Mellors, Patrick , Binder, Moritz , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Gonsalves, Wilson I. , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Kourelis, Taxiarchis , Warsame, Rahma , Zeldenrust, Steven R., Lust, John A., Kyle, Robert A. , Kumar, Shaji , Mellors, Patrick W , Buadi, Francis K. , Gonsalves, Wilson , Warsame, Rahma , Leung, Nelson , Go, Ronald S , Binder, Moritz , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | April 16, 2018 | Volume: 93 | Issue: 7 | Pages: 889-894

10.1002/ajh.25113 | PMID 29659048 Get It

AbstractResponse rates in newly diagnosed multiple myeloma have improved dramatically with the introduction of highly effective novel therapies. However, survival in patients achieving optimal responses to initial treatment can vary significantly, and new prognostic indicators are required to improve risk stratification. We investigated the relationship between time to plateau (TPlat) and survival in 1099 newly diagnosed patients treated with novel agents at our institution from 2005 to 2015.TPlatwas defined as time from initiation of first‐line therapy to best response to first‐line therapy. The medianTPlatwas 4.9 months (0.7‐58.6) and plateau duration was 1.8 years (0.2‐11.0). Patients who required > 120 days to achieve a plateau had longer modified overall survival (mOS) and progression free survival (mPFS) calculated from a landmark of best response (P < .001 for both comparisons). Statistically significant improvement in mOS was retained in subgroup analysis based on age and whether patients received upfront autologous hematopoietic stem cell transplantation (ASCT) (P < .001 for all comparisons). Our results suggest that patients who respond more gradually to initial therapy (TPlat > 120 days) experience longer survival compared to more rapid responders. Patients with a prolongedTPlatcould represent an “ongoing responder” phenotype that portends a survival advantage independent of treatment with upfront ASCT, depth of response, and biologic markers such as ISS stage and cytogenetic risk.